Asthma ExacerbationsBEAMNCT07486401
Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
A study testing Biomarker-directed treatment for asthma management in people with Asthma Exacerbations and Biomarkers / Blood, run by National Healthcare Group Polyclinics at 1 site in Singapore.
Trial summary
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better… Read more about this study
- Who is it for?
- Ages 21 to 65 years
- Conditions the study is for
- Asthma Exacerbations, Biomarkers / Blood, Eosinophil Blood Count
- What is being tested?
- Biomarker-directed treatment for asthma management
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 1 siteSingapore
- Study dates
- 3 Dec 2025to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Singaporeans or Singapore Permanent Residents
- Patients aged ≥21 to 65 years old
- Physician diagnosed asthma for duration of at least 4 weeks
- On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
- No asthma exacerbations* in the preceding 4 weeks before randomisation
- Able and willing to attend study appointments approximately every 4-monthly over a 1-year period
- Able to provide informed consent
- Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) *Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization
Who cannot join
- History of life-threatening asthma requiring intubation or intensive care unit admission
- Severe asthma or difficult to treat asthma
- Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
- Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
- Current use of beta-blocking agents including eye-drops
- Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
Show all 12Show fewer
- Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis
- Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
- Current enrolment in other interventional clinical trial for asthma
- Female subjects who are pregnant or planning pregnancy during the study period
- Planned travel outside of the country for ≥16 consecutive weeks during the study
- Investigator's assessment of poor capability of following study instructions or comply with study procedures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
National Healthcare Group Polyclinics
Singapore, 308205
Wern Ee Tang, (65) 6355 3000, wern.ee.tang@nhghealth.com.sg
About this study
Official title: Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.
The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.
Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management
- Being tested
- Biomarker-directed treatment for asthma management, Usual Care
- Keywords
- Asthma, Mild-moderate Asthma, Blood Biomarkers, Eosinophil, Primary Care
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biomarker-directed treatment for asthma managementDiagnostic test
Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
Usual CareOther
Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils
| Study group | Role | What they receive |
|---|---|---|
| Biomarker-Directed Arm | Active comparator | Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed). Receives: Diagnostic Test: Biomarker-directed treatment for asthma management |
| Control Arm (Usual Care) | Other | Participants in the control arm will receive usual care, this does not involve the use of blood eosinophils Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first asthma exacerbation requiring hospitalisation
Time to first asthma exacerbation requiring hospitalisation comparing usual care vs biomarker-directed care measured in days.
Measured: Within 12 months from enrollment
Number of asthma exacerbations not requiring hospitalisation
Number of asthma exacerbations not requiring hospitalisation comparing usual care vs biomarker-directed care measured via counts.
Measured: From enrollment to 12 months
Worsening of asthma symptoms
Worsening of asthma symptoms based on Asthma Control Test Score (ACT score decrease ≥3 points from baseline) comparing usual care vs biomarker-directed care measured based on scores and percentage of scores.
Measured: From enrollment to 12 months
Secondary outcomes (8)
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits (outpatient, ED, admissions) measured via counts.
Measured: From enrollment to 12 months
Change in Asthma Quality of Life Questionnaire score
Change in asthma quality of life questionnaire (AQLQ) score from baseline measure via score points ranging from 1-7, with higher scores indicating better quality of life.
Measured: From enrollment to 12 months
Change in Asthma Control Test score
Change in Asthma Control Test (ACT) scores from baseline measure via score points ranging from 5-25, with higher scores indicating better asthma control.
Measured: From enrollment to 12 months
Change in Global Initiative for Asthma score
Change in Global Initiative for Asthma (GINA) scores from baseline measure via score points ranging from 0-4, with lower scores indicating better asthma control.
Measured: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second
Changes in Forced Expiratory Volume in 1 second (FEV1) from spirometry test, measured in litres, percentages and litres per second. Lower FEV1 value indicates lung obstruction.
Measured: From enrollment to 12 months
Changes in Forced Vital Capacity
Changes in Forced Vital Capacity (FVC) from spirometry test, measured in litres, percentages and litres per second. Lower FVC value indicates lung obstruction.
Measured: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second/Forced Vital Capacity Ratio
Changes in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio from spirometry test, measured in litres, percentages and litres per second. FEV1/FVC below 0.70 typically indicates airway obstruction.
Measured: From enrollment to 12 months
Changes in Peak Expiratory Flow
Changes in Peak Expiratory Flow (PEF) from spirometry test, measured in litres, percentages and litres per second. Higher PEF value indicates good asthma control.
Measured: From enrollment to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start3 Dec 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma ExacerbationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study aims to evaluate the feasibility of using blood eosinophil as a biomarker-directed treatment for the management of mid-moderate asthmatic patients in primary care.
- Masking
- None (open label)
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Healthcare Group Polyclinics
- Sponsor type
- Other government
- Collaborators
- National Medical Research Council (NMRC), Singapore, Singapore General Hospital
- Responsible party
- Principal investigator, Wern Ee Tang, National Healthcare Group Polyclinics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07486401
- Sponsor's protocol ID
- 2024-4243
- Acronym
- BEAM
- Status last verified
- Mar 2026
- First submitted
- 5 Dec 2025
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
- ClinicalTrials.gov ID
- NCT07486401
- Acronym / sponsor ID
- BEAM / 2024-4243
- Keywords
- Asthma, Mild-moderate Asthma, Blood Biomarkers, Eosinophil, Primary Care
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- National Healthcare Group PolyclinicsOther government
- Collaborators
- National Medical Research Council (NMRC), Singapore, Singapore General Hospital
- Study start
- 3 Dec 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting.
The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.
Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study aims to evaluate the feasibility of using blood eosinophil as a biomarker-directed treatment for the management of mid-moderate asthmatic patients in primary care.
| Arm | Type | Receives |
|---|---|---|
| Biomarker-Directed Arm | Active comparator | Diagnostic Test: Biomarker-directed treatment for asthma managementAsthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed). |
| Control Arm (Usual Care) | Other | Other: Usual CareParticipants in the control arm will receive usual care, this does not involve the use of blood eosinophils |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Singaporeans or Singapore Permanent Residents
- Patients aged ≥21 to 65 years old
- Physician diagnosed asthma for duration of at least 4 weeks
- On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
- No asthma exacerbations* in the preceding 4 weeks before randomisation
Key exclusion criteria (12 listed)
- History of life-threatening asthma requiring intubation or intensive care unit admission
- Severe asthma or difficult to treat asthma
- Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
- Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
- Current use of beta-blocking agents including eye-drops
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biomarker-directed treatment for asthma managementAsthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed). | Diagnostic test | Biomarker-Directed Arm |
| Usual CareParticipants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils | Other | Control Arm (Usual Care) |
Primary outcome
Time to first asthma exacerbation requiring hospitalisation
Time frame: Within 12 months from enrollment
Time to first asthma exacerbation requiring hospitalisation comparing usual care vs biomarker-directed care measured in days.
Number of asthma exacerbations not requiring hospitalisation
Time frame: From enrollment to 12 months
Number of asthma exacerbations not requiring hospitalisation comparing usual care vs biomarker-directed care measured via counts.
Worsening of asthma symptoms
Time frame: From enrollment to 12 months
Worsening of asthma symptoms based on Asthma Control Test Score (ACT score decrease ≥3 points from baseline) comparing usual care vs biomarker-directed care measured based on scores and percentage of scores.
8 secondary outcomes
Asthma exacerbations requiring systemic corticosteroids and urgent healthcare visits
Time frame: From enrollment to 12 months
Change in Asthma Quality of Life Questionnaire score
Time frame: From enrollment to 12 months
Change in Asthma Control Test score
Time frame: From enrollment to 12 months
Change in Global Initiative for Asthma score
Time frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second
Time frame: From enrollment to 12 months
Changes in Forced Vital Capacity
Time frame: From enrollment to 12 months
Changes in Forced Expiratory Volume in 1 second/Forced Vital Capacity Ratio
Time frame: From enrollment to 12 months
Changes in Peak Expiratory Flow
Time frame: From enrollment to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Asthma Exacerbations
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruitingPhase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Not yet recruiting
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
Pediatric Asthma, Acute Asthma
Recruiting
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
Asthma Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biomarker-directed treatment for asthma management in people with Asthma Exacerbations and Biomarkers / Blood, run by National Healthcare Group Polyclinics at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wern Ee Tang ((65) 6355 3000, wern.ee.tang@nhghealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first asthma exacerbation requiring hospitalisation (time frame: Within 12 months from enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.